<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240910223724&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240910223724&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Wed, 11 Sep 2024 02:37:25 +0000</lastbuilddate>
<pubDate>Tue, 10 Sep 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Tackling difficult clinical scenarios on cardiovascular disease in the peripartum period: meeting reports from Pregnancy and the Heart Symposia in Cape Town and Mauritius</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39254051/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240910223724&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 10:ehae434. doi: 10.1093/eurheartj/ehae434. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39254051/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240910223724&v=2.18.0.post9+e462414">39254051</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae434>10.1093/eurheartj/ehae434</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39254051</guid>
<pubDate>Tue, 10 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Blanche Cupido</dc:creator>
<dc:creator>Sanjay Bucktowar</dc:creator>
<dc:creator>Karen Sliwa</dc:creator>
<dc:date>2024-09-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Tackling difficult clinical scenarios on cardiovascular disease in the peripartum period: meeting reports from Pregnancy and the Heart Symposia in Cape Town and Mauritius</dc:title>
<dc:identifier>pmid:39254051</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae434</dc:identifier>
</item>
<item>
<title>What is the role of sex and gender in the future of precision cardiology?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39254039/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240910223724&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 10:ehae504. doi: 10.1093/eurheartj/ehae504. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39254039/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240910223724&v=2.18.0.post9+e462414">39254039</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae504>10.1093/eurheartj/ehae504</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39254039</guid>
<pubDate>Tue, 10 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Stefano Ministrini</dc:creator>
<dc:creator>Teresa Padró</dc:creator>
<dc:date>2024-09-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>What is the role of sex and gender in the future of precision cardiology?</dc:title>
<dc:identifier>pmid:39254039</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae504</dc:identifier>
</item>
<item>
<title>Cardio-oncology 2023: insights from the National Societies of Cardiology Journals of the European Society of Cardiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39254038/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240910223724&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 10:ehae493. doi: 10.1093/eurheartj/ehae493. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39254038/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240910223724&v=2.18.0.post9+e462414">39254038</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae493>10.1093/eurheartj/ehae493</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39254038</guid>
<pubDate>Tue, 10 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Jean-Jacques Monsuez</dc:creator>
<dc:creator>Plamen Gatzov</dc:creator>
<dc:creator>Fernando Alfonso</dc:creator>
<dc:creator>Editors Network of the National Societies of Cardiology Journals, European Society of Cardiology</dc:creator>
<dc:date>2024-09-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Cardio-oncology 2023: insights from the National Societies of Cardiology Journals of the European Society of Cardiology</dc:title>
<dc:identifier>pmid:39254038</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae493</dc:identifier>
</item>
<item>
<title>Integration of a hypertension treatment programme into Nigeria's primary healthcare system: report from a stakeholders and policymakers' workshop</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39254029/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240910223724&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 10:ehae376. doi: 10.1093/eurheartj/ehae376. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39254029/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240910223724&v=2.18.0.post9+e462414">39254029</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae376>10.1093/eurheartj/ehae376</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39254029</guid>
<pubDate>Tue, 10 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Chisom Obiezu-Umeh</dc:creator>
<dc:creator>Mark D Huffman</dc:creator>
<dc:creator>Dike B Ojji</dc:creator>
<dc:date>2024-09-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Integration of a hypertension treatment programme into Nigeria's primary healthcare system: report from a stakeholders and policymakers' workshop</dc:title>
<dc:identifier>pmid:39254029</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae376</dc:identifier>
</item>
<item>
<title>Promoting a healthier Ramadan: addressing mind, body, soul, and heart wellbeing</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39254028/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240910223724&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 10:ehae456. doi: 10.1093/eurheartj/ehae456. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39254028/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240910223724&v=2.18.0.post9+e462414">39254028</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae456>10.1093/eurheartj/ehae456</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39254028</guid>
<pubDate>Tue, 10 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Mohammed Y Khanji</dc:creator>
<dc:creator>Waheeb Al-Azzani</dc:creator>
<dc:creator>Shams Abdalla</dc:creator>
<dc:creator>Salman Waqar</dc:creator>
<dc:date>2024-09-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Promoting a healthier Ramadan: addressing mind, body, soul, and heart wellbeing</dc:title>
<dc:identifier>pmid:39254028</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae456</dc:identifier>
</item>
<item>
<title>IRS2 Signaling Protects Against Stress-Induced Arrhythmia by Maintaining Ca&lt;sup>;2+&lt;/sup>; Homeostasis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39253856/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240910223724&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Cardiac IRS2 inhibits sympathetic stress-induced AKT/NOS3/CaMKII/RyR2 overactivation and calcium-dependent arrhythmogenesis. This novel IRS2 signaling axis, essential for maintaining cardiac calcium homeostasis under stress, presents a promising target for developing new antiarrhythmic therapies.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 10. doi: 10.1161/CIRCULATIONAHA.123.065048. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The docking protein IRS2 (insulin receptor substrate protein-2) is an important mediator of insulin signaling and may also regulate other signaling pathways. Murine hearts with cardiomyocyte-restricted deletion of <i>IRS2</i> (cIRS2-KO) are more susceptible to pressure overload-induced cardiac dysfunction, implying a critical protective role of IRS2 in cardiac adaptation to stress through mechanisms that are not fully understood. There is limited evidence regarding the function of IRS2 beyond metabolic homeostasis regulation, particularly in the context of cardiac disease.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A retrospective analysis of an electronic medical record database was conducted to identify patients with <i>IRS2</i> variants and assess their risk of cardiac arrhythmias. Arrhythmia susceptibility was examined in cIRS2-KO mice. The underlying mechanisms were investigated using confocal calcium imaging of ex vivo whole hearts and isolated cardiomyocytes to assess calcium handling, Western blotting to analyze the involved signaling pathways, and pharmacological and genetic interventions to rescue arrhythmias in cIRS2-KO mice.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The retrospective analysis identified patients with <i>IRS2</i> variants of uncertain significance with a potential association to an increased risk of cardiac arrhythmias compared with matched controls. cIRS2-KO hearts were found to be prone to catecholamine-sensitive ventricular tachycardia and reperfusion ventricular tachycardia. Confocal calcium imaging of ex vivo whole hearts and single isolated cardiomyocytes from cIRS2-KO hearts revealed decreased Ca²<sup>+</sup> transient amplitudes, increased spontaneous Ca²<sup>+</sup> sparks, and reduced sarcoplasmic reticulum Ca²<sup>+</sup> content during sympathetic stress, indicating sarcoplasmic reticulum dysfunction. We identified that overactivation of the AKT1/NOS3 (nitric oxide synthase 3)/CaMKII (Ca2+/calmodulin-dependent protein kinase II)/RyR2 (type 2 ryanodine receptor) signaling pathway led to calcium mishandling and catecholamine-sensitive ventricular tachycardia in cIRS2-KO hearts. Pharmacological AKT inhibition or genetic stabilization of RyR2 rescued catecholamine-sensitive ventricular tachycardia in cIRS2-KO mice.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Cardiac IRS2 inhibits sympathetic stress-induced AKT/NOS3/CaMKII/RyR2 overactivation and calcium-dependent arrhythmogenesis. This novel IRS2 signaling axis, essential for maintaining cardiac calcium homeostasis under stress, presents a promising target for developing new antiarrhythmic therapies.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39253856/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240910223724&v=2.18.0.post9+e462414">39253856</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065048>10.1161/CIRCULATIONAHA.123.065048</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39253856</guid>
<pubDate>Tue, 10 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Qian Shi</dc:creator>
<dc:creator>Jinxi Wang</dc:creator>
<dc:creator>Hamza Malik</dc:creator>
<dc:creator>Xuguang Li</dc:creator>
<dc:creator>Jennifer Streeter</dc:creator>
<dc:creator>Jacob Sharafuddin</dc:creator>
<dc:creator>Eric Weatherford</dc:creator>
<dc:creator>David Stein</dc:creator>
<dc:creator>Yuval Itan</dc:creator>
<dc:creator>Biyi Chen</dc:creator>
<dc:creator>Duane Hall</dc:creator>
<dc:creator>Long-Sheng Song</dc:creator>
<dc:creator>E Dale Abel</dc:creator>
<dc:date>2024-09-10</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>IRS2 Signaling Protects Against Stress-Induced Arrhythmia by Maintaining Ca&lt;sup>;2+&lt;/sup>; Homeostasis</dc:title>
<dc:identifier>pmid:39253856</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065048</dc:identifier>
</item>
<item>
<title>Glucosamine-Mediated Hexosamine Biosynthesis Pathway Activation Uses ATF4 to Promote "Exercise-Like" Angiogenesis and Perfusion Recovery in PAD</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39253813/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240910223724&amp;v=2.18.0.post9+e462414
      <description>CONCLUSION: In cells, mice, and humans, activation of hexosamine biosynthesis pathway by glucosamine in peripheral arterial disease induces an "exercise-like" angiogenesis and offers a promising novel therapeutic pathway to treat this challenging disorder.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 10. doi: 10.1161/CIRCULATIONAHA.124.069580. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Endothelial cells (ECs) use glycolysis to produce energy. In preclinical models of peripheral arterial disease, further activation of EC glycolysis was ineffective or deleterious in promoting hypoxia-dependent angiogenesis, whereas pentose phosphate pathway activation was effective. Hexosamine biosynthesis pathway, pentose phosphate pathway, and glycolysis are closely linked. Glucosamine directly activates hexosamine biosynthesis pathway.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Hind-limb ischemia in endothelial nitric oxide synthase knockout (eNOS<sup>-/-</sup>) and BALB/c mice was used. Glucosamine (600 μg/g per day) was injected intraperitoneally. Blood flow recovery was assessed using laser Doppler perfusion imaging and angiogenesis was studied by CD31 immunostaining. In vitro, human umbilical vein ECs and mouse microvascular ECs with glucosamine, L-glucose, or vascular endothelial growth factor (VEGF<sub>165</sub>a) were tested under hypoxia and serum starvation. Cell Counting Kit-8, tube formation, intracellular reactive oxygen species, electric cell-substrate impedance sensing, and fluorescein isothiocyanate dextran permeability were assessed. Glycolysis and oxidative phosphorylation were assessed by seahorse assay. Gene expression was assessed using RNA sequencing, real-time quantitative polymerase chain reaction, and Western blot. Human muscle biopsies from patients with peripheral arterial disease were assessed for EC O-GlcNAcylation before and after supervised exercise versus standard medical care.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: On day 3 after hind-limb ischemia, glucosamine-treated versus control eNOS<sup>-/-</sup> mice had less necrosis (n=4 or 5 per group). Beginning on day 7 after hind-limb ischemia, glucosamine-treated versus control BALB/c mice had higher blood flow, which persisted to day 21, when ischemic muscles showed greater CD31 staining per muscle fiber (n=8 per group). In vitro, glucosamine versus L-glucose ECs showed improved survival (n=6 per group) and tube formation (n=6 per group). RNA sequencing of glucosamine versus L-glucose ECs showed increased amino acid metabolism (n=3 per group). That resulted in increased oxidative phosphorylation (n=8-12 per group) and serine biosynthesis pathway without an increase in glycolysis or pentose phosphate pathway genes (n=6 per group). This was associated with better barrier function (n=6-8 per group) and less reactive oxygen species (n=7 or 8 per group) compared with activating glycolysis by VEGF<sub>165</sub>a. These effects were mediated by activating transcription factor 4, a driver of exercise-induced angiogenesis. In muscle biopsies from humans with peripheral arterial disease, EC/O-GlcNAcylation was increased by 12 weeks of supervised exercise versus standard medical care (n=6 per group).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSION: In cells, mice, and humans, activation of hexosamine biosynthesis pathway by glucosamine in peripheral arterial disease induces an "exercise-like" angiogenesis and offers a promising novel therapeutic pathway to treat this challenging disorder.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39253813/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240910223724&v=2.18.0.post9+e462414">39253813</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069580>10.1161/CIRCULATIONAHA.124.069580</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39253813</guid>
<pubDate>Tue, 10 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Suhib Alhusban</dc:creator>
<dc:creator>Mohamed Nofal</dc:creator>
<dc:creator>Anita Kovacs-Kasa</dc:creator>
<dc:creator>Taylor C Kress</dc:creator>
<dc:creator>M Murat Koseoglu</dc:creator>
<dc:creator>Abdelrahman A Zaied</dc:creator>
<dc:creator>Eric J Belin de Chantemele</dc:creator>
<dc:creator>Brian H Annex</dc:creator>
<dc:date>2024-09-10</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Glucosamine-Mediated Hexosamine Biosynthesis Pathway Activation Uses ATF4 to Promote "Exercise-Like" Angiogenesis and Perfusion Recovery in PAD</dc:title>
<dc:identifier>pmid:39253813</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069580</dc:identifier>
</item>
<item>
<title>Evaluation and Management of Kidney Dysfunction in Advanced Heart Failure: A Scientific Statement From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39253806/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240910223724&amp;v=2.18.0.post9+e462414
      <description>Early identification of kidney dysfunction in patients with advanced heart failure is crucial for timely interventions. In addition to elevations in serum creatinine, kidney dysfunction encompasses inadequate maintenance of sodium and volume homeostasis, retention of uremic solutes, and disrupted endocrine functions. Hemodynamic derangements and maladaptive neurohormonal upregulations contribute to fluctuations in kidney indices and electrolytes that may recover with guideline-directed medical...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 10. doi: 10.1161/CIR.0000000000001273. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Early identification of kidney dysfunction in patients with advanced heart failure is crucial for timely interventions. In addition to elevations in serum creatinine, kidney dysfunction encompasses inadequate maintenance of sodium and volume homeostasis, retention of uremic solutes, and disrupted endocrine functions. Hemodynamic derangements and maladaptive neurohormonal upregulations contribute to fluctuations in kidney indices and electrolytes that may recover with guideline-directed medical therapy. Quantifying the extent of underlying irreversible intrinsic kidney disease is crucial in predicting whether optimization of congestion and guideline-directed medical therapy can stabilize kidney function. This scientific statement focuses on clinical management of patients experiencing kidney dysfunction through the trajectory of advanced heart failure, with specific focus on (1) the conceptual framework for appropriate evaluation of kidney dysfunction within the context of clinical trajectories in advanced heart failure, including in the consideration of advanced heart failure therapies; (2) preoperative, perioperative, and postoperative approaches to evaluation and management of kidney disease for advanced surgical therapies (durable left ventricular assist device/heart transplantation) and kidney replacement therapies; and (3) the key concepts in palliative care and decision-making processes unique to individuals with concomitant advanced heart failure and kidney disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39253806/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240910223724&v=2.18.0.post9+e462414">39253806</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001273>10.1161/CIR.0000000000001273</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39253806</guid>
<pubDate>Tue, 10 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>W H Wilson Tang</dc:creator>
<dc:creator>Marie A Bakitas</dc:creator>
<dc:creator>Xingxing S Cheng</dc:creator>
<dc:creator>James C Fang</dc:creator>
<dc:creator>Savitri E Fedson</dc:creator>
<dc:creator>Amy G Fiedler</dc:creator>
<dc:creator>Pieter Martens</dc:creator>
<dc:creator>Wendy I McCallum</dc:creator>
<dc:creator>Modele O Ogunniyi</dc:creator>
<dc:creator>Janani Rangaswami</dc:creator>
<dc:creator>Nisha Bansal</dc:creator>
<dc:creator>American Heart Association Council on the Kidney in Cardiovascular Disease; Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Hypertension; and Council on Quality of Care and Outcomes Research</dc:creator>
<dc:date>2024-09-10</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Evaluation and Management of Kidney Dysfunction in Advanced Heart Failure: A Scientific Statement From the American Heart Association</dc:title>
<dc:identifier>pmid:39253806</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001273</dc:identifier>
</item>
<item>
<title>Half-Life and Clearance of Cardiac Troponin I and Troponin T in Humans</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39253802/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240910223724&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This novel method showed that the elimination half-life of cTnI and cTnT was 5 to 16 hours shorter than previously reported. This indicates a considerably longer duration of cardiomyocyte cTn release after MI than previously thought. Improved knowledge of timing of myocardial injury may call for changes in the management of MI and other disorders with myocardial injury.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 10. doi: 10.1161/CIRCULATIONAHA.123.066565. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Cardiac troponin (cTn) is key in diagnosing myocardial infarction (MI). After MI, the clinically observed half-life of cTn has been reported to be 7 to 20 hours, but this estimate reflects the combined elimination and simultaneous release of cTn from cardiomyocytes. More precise timing of myocardial injuries necessitates separation of these 2 components. We used a novel method for determination of isolated cTn elimination kinetics in humans.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients with MI were included within 24 hours after revascularization and underwent plasmapheresis to obtain plasma with a high cTn concentration. After at least 3 weeks, patients returned for an autologous plasma retransfusion followed by blood sampling for 8 hours. cTn was measured with 5 different high-sensitivity cTn assays.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 25 included patients, 20 participants (mean age, 64.5 years; SD, 8.2 years; 4 women [20%]) received a retransfusion after a median of 5.8 weeks (interquartile range, 5.0-6.9 weeks) after MI. After retransfusion of a median of 620 mL (range, 180-679 mL) autologous plasma, the concentration of cTn in participants' blood increased 4 to 445 times above the upper reference level of the 5 high-sensitivity cTn assays. The median elimination half-life ranged from 134.1 minutes (95% CI, 117.8-168.0) for the Elecsys high-sensitivity cTnT assay to 239.7 minutes (95% CI, 153.7-295.1) for the Vitros high-sensitivity cTnI assay. The median clearance of cTnI ranged from 40.3 mL/min (95% CI, 32.0-44.9) to 52.7 mL/min (95% CI, 42.2-57.8). The clearance of cTnT was 77.0 mL/min (95% CI, 45.2-95.0).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This novel method showed that the elimination half-life of cTnI and cTnT was 5 to 16 hours shorter than previously reported. This indicates a considerably longer duration of cardiomyocyte cTn release after MI than previously thought. Improved knowledge of timing of myocardial injury may call for changes in the management of MI and other disorders with myocardial injury.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39253802/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240910223724&v=2.18.0.post9+e462414">39253802</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066565>10.1161/CIRCULATIONAHA.123.066565</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39253802</guid>
<pubDate>Tue, 10 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Jonas Henrik Kristensen</dc:creator>
<dc:creator>Rasmus Bo Hasselbalch</dc:creator>
<dc:creator>Nina Strandkjær</dc:creator>
<dc:creator>Nicoline Jørgensen</dc:creator>
<dc:creator>Morten Østergaard</dc:creator>
<dc:creator>Peter Hasse Møller-Sørensen</dc:creator>
<dc:creator>Jens Christian Nilsson</dc:creator>
<dc:creator>Shoaib Afzal</dc:creator>
<dc:creator>Pia Rørbæk Kamstrup</dc:creator>
<dc:creator>Morten Dahl</dc:creator>
<dc:creator>Mustafa Vakur Bor</dc:creator>
<dc:creator>Ruth Frikke-Schmidt</dc:creator>
<dc:creator>Niklas Rye Jørgensen</dc:creator>
<dc:creator>Line Rode</dc:creator>
<dc:creator>Lene Holmvang</dc:creator>
<dc:creator>Jesper Kjærgaard</dc:creator>
<dc:creator>Lia Evi Bang</dc:creator>
<dc:creator>Julie Forman</dc:creator>
<dc:creator>Kim Dalhoff</dc:creator>
<dc:creator>Allan S Jaffe</dc:creator>
<dc:creator>Kristian Thygesen</dc:creator>
<dc:creator>Henning Bundgaard</dc:creator>
<dc:creator>Kasper Karmark Iversen</dc:creator>
<dc:date>2024-09-10</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Half-Life and Clearance of Cardiac Troponin I and Troponin T in Humans</dc:title>
<dc:identifier>pmid:39253802</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066565</dc:identifier>
</item>
<item>
<title>Heart failure with preserved ejection fraction: underdiagnosed and undertreated in patients with tricuspid regurgitation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39250731/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240910223724&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 9:ehae544. doi: 10.1093/eurheartj/ehae544. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39250731/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240910223724&v=2.18.0.post9+e462414">39250731</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae544>10.1093/eurheartj/ehae544</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39250731</guid>
<pubDate>Mon, 09 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Khawaja M Talha</dc:creator>
<dc:creator>Marco Metra</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:date>2024-09-09</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Heart failure with preserved ejection fraction: underdiagnosed and undertreated in patients with tricuspid regurgitation</dc:title>
<dc:identifier>pmid:39250731</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae544</dc:identifier>
</item>
<item>
<title>Management of aortic disease in children with FBN1-related Marfan syndrome</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39250726/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240910223724&amp;v=2.18.0.post9+e462414
      <description>Marfan syndrome (MFS) is a hereditary connective tissue disorder with an estimated prevalence of 1:5000-1:10 000 individuals. It is a pleiotropic disease characterized by specific ocular, cardiovascular, and skeletal features. The most common cardiovascular complication is aortic root dilatation which untreated can lead to life-threatening aortic root dissection, mainly occurring in adult patients. Prompt diagnosis, appropriate follow-up, and timely treatment can prevent aortic events. Currently...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 9:ehae526. doi: 10.1093/eurheartj/ehae526. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Marfan syndrome (MFS) is a hereditary connective tissue disorder with an estimated prevalence of 1:5000-1:10 000 individuals. It is a pleiotropic disease characterized by specific ocular, cardiovascular, and skeletal features. The most common cardiovascular complication is aortic root dilatation which untreated can lead to life-threatening aortic root dissection, mainly occurring in adult patients. Prompt diagnosis, appropriate follow-up, and timely treatment can prevent aortic events. Currently there are no specific recommendations for treatment of children with MFS, and management is greatly based on adult guidelines. Furthermore, due to the scarcity of studies including children, there is a lack of uniform treatment across different centres. This consensus document aims at bridging these gaps of knowledge. This work is a joint collaboration between the paediatric subgroup of the European Network of Vascular Diseases (VASCERN, Heritable Thoracic Aortic Disease Working Group) and the Association for European Paediatric and Congenital Cardiology (AEPC). A group of experts from 12 different centres and 8 different countries participated in this effort. This document reviews four main subjects, namely, (i) imaging of the aorta at diagnosis and follow-up, (ii) recommendations on medical treatment, (iii) recommendations on surgical treatment, and (iv) recommendations on sport participation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39250726/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240910223724&v=2.18.0.post9+e462414">39250726</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae526>10.1093/eurheartj/ehae526</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39250726</guid>
<pubDate>Mon, 09 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Laura Muiño-Mosquera</dc:creator>
<dc:creator>Elena Cervi</dc:creator>
<dc:creator>Katya De Groote</dc:creator>
<dc:creator>Wendy Dewals</dc:creator>
<dc:creator>Zina Fejzic</dc:creator>
<dc:creator>Kalliopi Kazamia</dc:creator>
<dc:creator>Sujeev Mathur</dc:creator>
<dc:creator>Olivier Milleron</dc:creator>
<dc:creator>Thomas S Mir</dc:creator>
<dc:creator>Dorte G Nielsen</dc:creator>
<dc:creator>Michal Odermarsky</dc:creator>
<dc:creator>Anna Sabate-Rotes</dc:creator>
<dc:creator>Annelies van der Hulst</dc:creator>
<dc:creator>Irene Valenzuela</dc:creator>
<dc:creator>Guillaume Jondeau</dc:creator>
<dc:date>2024-09-09</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Management of aortic disease in children with FBN1-related Marfan syndrome</dc:title>
<dc:identifier>pmid:39250726</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae526</dc:identifier>
</item>
<item>
<title>Quantifying Longevity After Myocardial Infarction: What Is Lost and What Is Gained</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39250540/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240910223724&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 10;150(11):836-837. doi: 10.1161/CIRCULATIONAHA.124.070996. Epub 2024 Sep 9.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39250540/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240910223724&v=2.18.0.post9+e462414">39250540</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070996>10.1161/CIRCULATIONAHA.124.070996</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39250540</guid>
<pubDate>Mon, 09 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Neel M Butala</dc:creator>
<dc:creator>Emily M Bucholz</dc:creator>
<dc:date>2024-09-09</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Quantifying Longevity After Myocardial Infarction: What Is Lost and What Is Gained</dc:title>
<dc:identifier>pmid:39250540</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070996</dc:identifier>
</item>
<item>
<title>Noninferiority Clinical Trials: Overview for the Clinical Cardiologist</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39250539/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240910223724&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 10;150(11):823-825. doi: 10.1161/CIRCULATIONAHA.124.068928. Epub 2024 Sep 9.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39250539/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240910223724&v=2.18.0.post9+e462414">39250539</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068928>10.1161/CIRCULATIONAHA.124.068928</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39250539</guid>
<pubDate>Mon, 09 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Sabina A Murphy</dc:creator>
<dc:creator>Andrea Bellavia</dc:creator>
<dc:date>2024-09-09</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Noninferiority Clinical Trials: Overview for the Clinical Cardiologist</dc:title>
<dc:identifier>pmid:39250539</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068928</dc:identifier>
</item>
<item>
<title>Genetic and Pharmacologic Inhibition of JAK1/2 Antagonizes Cardiac Fibrosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39250538/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240910223724&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 10;150(11):899-901. doi: 10.1161/CIRCULATIONAHA.124.070340. Epub 2024 Sep 9.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39250538/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240910223724&v=2.18.0.post9+e462414">39250538</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070340>10.1161/CIRCULATIONAHA.124.070340</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39250538</guid>
<pubDate>Mon, 09 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Qinghang Meng</dc:creator>
<dc:creator>Bo Yang</dc:creator>
<dc:creator>Yan Qiao</dc:creator>
<dc:creator>Yingxin Wu</dc:creator>
<dc:creator>Jie Chen</dc:creator>
<dc:creator>Xinhua Lin</dc:creator>
<dc:creator>Jeffery D Molkentin</dc:creator>
<dc:date>2024-09-09</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Genetic and Pharmacologic Inhibition of JAK1/2 Antagonizes Cardiac Fibrosis</dc:title>
<dc:identifier>pmid:39250538</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070340</dc:identifier>
</item>
<item>
<title>Targeting Fibrinolytic Inhibition for Venous Thromboembolism Treatment: Overview of an Emerging Therapeutic Approach</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39250537/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240910223724&amp;v=2.18.0.post9+e462414
      <description>Venous thrombosis and pulmonary embolism (venous thromboembolism) are important causes of morbidity and mortality worldwide. In patients with venous thromboembolism, thrombi obstruct blood vessels and resist physiological dissolution (fibrinolysis), which can be life threatening and cause chronic complications. Plasminogen activator therapy, which was developed >;50 years ago, is effective in dissolving thrombi but has unacceptable bleeding risks. Safe dissolution of thrombi in patients with...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 10;150(11):884-898. doi: 10.1161/CIRCULATIONAHA.124.069728. Epub 2024 Sep 9.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Venous thrombosis and pulmonary embolism (venous thromboembolism) are important causes of morbidity and mortality worldwide. In patients with venous thromboembolism, thrombi obstruct blood vessels and resist physiological dissolution (fibrinolysis), which can be life threatening and cause chronic complications. Plasminogen activator therapy, which was developed >;50 years ago, is effective in dissolving thrombi but has unacceptable bleeding risks. Safe dissolution of thrombi in patients with venous thromboembolism has been elusive despite multiple innovations in plasminogen activator design and catheter-based therapy. Evidence now suggests that fibrinolysis is rigidly controlled by endogenous fibrinolysis inhibitors, including α2-antiplasmin, plasminogen activator inhibitor-1, and thrombin-activable fibrinolysis inhibitor. Elevated levels of these fibrinolysis inhibitors are associated with an increased risk of venous thromboembolism in humans. New therapeutic paradigms suggest that accelerated and effective fibrinolysis may be achieved safely by therapeutically targeting these fibrinolytic inhibitors in venous thromboembolism. In this article, we discuss the role of fibrinolytic components in venous thromboembolism and the current status of research and development targeting fibrinolysis inhibitors.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39250537/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240910223724&v=2.18.0.post9+e462414">39250537</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069728>10.1161/CIRCULATIONAHA.124.069728</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39250537</guid>
<pubDate>Mon, 09 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Satish Singh</dc:creator>
<dc:creator>Pardeep Kumar</dc:creator>
<dc:creator>Yogendra S Padwad</dc:creator>
<dc:creator>Farouc A Jaffer</dc:creator>
<dc:creator>Guy L Reed</dc:creator>
<dc:date>2024-09-09</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Targeting Fibrinolytic Inhibition for Venous Thromboembolism Treatment: Overview of an Emerging Therapeutic Approach</dc:title>
<dc:identifier>pmid:39250537</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069728</dc:identifier>
</item>
<item>
<title>Transcatheter Aortic Valve Implantation: Two Decades of a Revolutionary and Ongoing Odyssey</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39250536/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240910223724&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 10;150(11):821-822. doi: 10.1161/CIRCULATIONAHA.124.068237. Epub 2024 Sep 9.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39250536/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240910223724&v=2.18.0.post9+e462414">39250536</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068237>10.1161/CIRCULATIONAHA.124.068237</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39250536</guid>
<pubDate>Mon, 09 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Alain Cribier</dc:creator>
<dc:creator>Hélène Eltchaninoff</dc:creator>
<dc:date>2024-09-09</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Transcatheter Aortic Valve Implantation: Two Decades of a Revolutionary and Ongoing Odyssey</dc:title>
<dc:identifier>pmid:39250536</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068237</dc:identifier>
</item>
<item>
<title>Divergent sensory pathways of sneezing and coughing</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39243765/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240910223724&amp;v=2.18.0.post9+e462414
      <description>Sneezing and coughing are primary symptoms of many respiratory viral infections and allergies. It is generally assumed that sneezing and coughing involve common sensory receptors and molecular neurotransmission mechanisms. Here, we show that the nasal mucosa is innervated by several discrete populations of sensory neurons, but only one population (MrgprC11^(+)MrgprA3^(-)) mediates sneezing responses to a multitude of nasal irritants, allergens, and viruses. Although this population also...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Sep 4:S0092-8674(24)00900-0. doi: 10.1016/j.cell.2024.08.009. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Sneezing and coughing are primary symptoms of many respiratory viral infections and allergies. It is generally assumed that sneezing and coughing involve common sensory receptors and molecular neurotransmission mechanisms. Here, we show that the nasal mucosa is innervated by several discrete populations of sensory neurons, but only one population (MrgprC11<sup>+</sup>MrgprA3<sup>-</sup>) mediates sneezing responses to a multitude of nasal irritants, allergens, and viruses. Although this population also innervates the trachea, it does not mediate coughing, as revealed by our newly established cough model. Instead, a distinct sensory population (somatostatin [SST<sup>+</sup>]) mediates coughing but not sneezing, unraveling an unforeseen sensory difference between sneezing and coughing. At the circuit level, sneeze and cough signals are transmitted and modulated by divergent neuropathways. Together, our study reveals the difference in sensory receptors and neurotransmission/modulation mechanisms between sneezing and coughing, offering neuronal drug targets for symptom management in respiratory viral infections and allergies.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39243765/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240910223724&v=2.18.0.post9+e462414">39243765</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.08.009>10.1016/j.cell.2024.08.009</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39243765</guid>
<pubDate>Sat, 07 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Haowu Jiang</dc:creator>
<dc:creator>Huan Cui</dc:creator>
<dc:creator>Mengyu Chen</dc:creator>
<dc:creator>Fengxian Li</dc:creator>
<dc:creator>Xiaolei Shen</dc:creator>
<dc:creator>Changxiong J Guo</dc:creator>
<dc:creator>George E Hoekel</dc:creator>
<dc:creator>Yuyan Zhu</dc:creator>
<dc:creator>Liang Han</dc:creator>
<dc:creator>Kangyun Wu</dc:creator>
<dc:creator>Michael J Holtzman</dc:creator>
<dc:creator>Qin Liu</dc:creator>
<dc:date>2024-09-07</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Divergent sensory pathways of sneezing and coughing</dc:title>
<dc:identifier>pmid:39243765</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.08.009</dc:identifier>
</item>
<item>
<title>Sex-dependent effects in the aged melanoma tumor microenvironment influence invasion and resistance to targeted therapy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39243764/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240910223724&amp;v=2.18.0.post9+e462414
      <description>There is documented sex disparity in cutaneous melanoma incidence and mortality, increasing disproportionately with age and in the male sex. However, the underlying mechanisms remain unclear. While biological sex differences and inherent immune response variability have been assessed in tumor cells, the role of the tumor-surrounding microenvironment, contextually in aging, has been overlooked. Here, we show that skin fibroblasts undergo age-mediated, sex-dependent changes in their proliferation,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Sep 4:S0092-8674(24)00904-8. doi: 10.1016/j.cell.2024.08.013. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">There is documented sex disparity in cutaneous melanoma incidence and mortality, increasing disproportionately with age and in the male sex. However, the underlying mechanisms remain unclear. While biological sex differences and inherent immune response variability have been assessed in tumor cells, the role of the tumor-surrounding microenvironment, contextually in aging, has been overlooked. Here, we show that skin fibroblasts undergo age-mediated, sex-dependent changes in their proliferation, senescence, ROS levels, and stress response. We find that aged male fibroblasts selectively drive an invasive, therapy-resistant phenotype in melanoma cells and promote metastasis in aged male mice by increasing AXL expression. Intrinsic aging in male fibroblasts mediated by EZH2 decline increases BMP2 secretion, which in turn drives the slower-cycling, highly invasive, and therapy-resistant melanoma cell phenotype, characteristic of the aged male TME. Inhibition of BMP2 activity blocks the emergence of invasive phenotypes and sensitizes melanoma cells to BRAF/MEK inhibition.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39243764/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240910223724&v=2.18.0.post9+e462414">39243764</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.08.013>10.1016/j.cell.2024.08.013</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39243764</guid>
<pubDate>Sat, 07 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Yash Chhabra</dc:creator>
<dc:creator>Mitchell E Fane</dc:creator>
<dc:creator>Sneha Pramod</dc:creator>
<dc:creator>Laura Hüser</dc:creator>
<dc:creator>Daniel J Zabransky</dc:creator>
<dc:creator>Vania Wang</dc:creator>
<dc:creator>Agrani Dixit</dc:creator>
<dc:creator>Ruzhang Zhao</dc:creator>
<dc:creator>Edwin Kumah</dc:creator>
<dc:creator>Megan L Brezka</dc:creator>
<dc:creator>Kevin Truskowski</dc:creator>
<dc:creator>Asmita Nandi</dc:creator>
<dc:creator>Gloria E Marino-Bravante</dc:creator>
<dc:creator>Alexis E Carey</dc:creator>
<dc:creator>Naina Gour</dc:creator>
<dc:creator>Devon A Maranto</dc:creator>
<dc:creator>Murilo R Rocha</dc:creator>
<dc:creator>Elizabeth I Harper</dc:creator>
<dc:creator>Justin Ruiz</dc:creator>
<dc:creator>Evan J Lipson</dc:creator>
<dc:creator>Elizabeth M Jaffee</dc:creator>
<dc:creator>Kristin Bibee</dc:creator>
<dc:creator>Joel C Sunshine</dc:creator>
<dc:creator>Hongkai Ji</dc:creator>
<dc:creator>Ashani T Weeraratna</dc:creator>
<dc:date>2024-09-07</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Sex-dependent effects in the aged melanoma tumor microenvironment influence invasion and resistance to targeted therapy</dc:title>
<dc:identifier>pmid:39243764</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.08.013</dc:identifier>
</item>
<item>
<title>Small-molecule GSDMD agonism in tumors stimulates antitumor immunity without toxicity</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39243763/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240910223724&amp;v=2.18.0.post9+e462414
      <description>Gasdermin-mediated inflammatory cell death (pyroptosis) can activate protective immunity in immunologically cold tumors. Here, we performed a high-throughput screen for compounds that could activate gasdermin D (GSDMD), which is expressed widely in tumors. We identified 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline (DMB) as a direct and selective GSDMD agonist that activates GSDMD pore formation and pyroptosis without cleaving GSDMD. In mouse tumor models, pulsed and low-level...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Sep 2:S0092-8674(24)00898-5. doi: 10.1016/j.cell.2024.08.007. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Gasdermin-mediated inflammatory cell death (pyroptosis) can activate protective immunity in immunologically cold tumors. Here, we performed a high-throughput screen for compounds that could activate gasdermin D (GSDMD), which is expressed widely in tumors. We identified 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline (DMB) as a direct and selective GSDMD agonist that activates GSDMD pore formation and pyroptosis without cleaving GSDMD. In mouse tumor models, pulsed and low-level pyroptosis induced by DMB suppresses tumor growth without harming GSDMD-expressing immune cells. Protection is immune-mediated and abrogated in mice lacking lymphocytes. Vaccination with DMB-treated cancer cells protects mice from secondary tumor challenge, indicating that immunogenic cell death is induced. DMB treatment synergizes with anti-PD-1. DMB treatment does not alter circulating proinflammatory cytokine or leukocyte numbers or cause weight loss. Thus, our studies reveal a strategy that relies on a low level of tumor cell pyroptosis to induce antitumor immunity and raise the possibility of exploiting pyroptosis without causing overt toxicity.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39243763/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240910223724&v=2.18.0.post9+e462414">39243763</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.08.007>10.1016/j.cell.2024.08.007</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39243763</guid>
<pubDate>Sat, 07 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Pietro Fontana</dc:creator>
<dc:creator>Gang Du</dc:creator>
<dc:creator>Ying Zhang</dc:creator>
<dc:creator>Haiwei Zhang</dc:creator>
<dc:creator>Setu M Vora</dc:creator>
<dc:creator>Jun Jacob Hu</dc:creator>
<dc:creator>Ming Shi</dc:creator>
<dc:creator>Ahmet B Tufan</dc:creator>
<dc:creator>Liam B Healy</dc:creator>
<dc:creator>Shiyu Xia</dc:creator>
<dc:creator>Dian-Jang Lee</dc:creator>
<dc:creator>Zhouyihan Li</dc:creator>
<dc:creator>Pilar Baldominos</dc:creator>
<dc:creator>Heng Ru</dc:creator>
<dc:creator>Hongbo R Luo</dc:creator>
<dc:creator>Judith Agudo</dc:creator>
<dc:creator>Judy Lieberman</dc:creator>
<dc:creator>Hao Wu</dc:creator>
<dc:date>2024-09-07</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Small-molecule GSDMD agonism in tumors stimulates antitumor immunity without toxicity</dc:title>
<dc:identifier>pmid:39243763</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.08.007</dc:identifier>
</item>
<item>
<title>TGF-β and RAS jointly unmask primed enhancers to drive metastasis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39243762/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240910223724&amp;v=2.18.0.post9+e462414
      <description>Epithelial-to-mesenchymal transitions (EMTs) and extracellular matrix (ECM) remodeling are distinct yet important processes during carcinoma invasion and metastasis. Transforming growth factor β (TGF-β) and RAS, signaling through SMAD and RAS-responsive element-binding protein 1 (RREB1), jointly trigger expression of EMT and fibrogenic factors as two discrete arms of a common transcriptional response in carcinoma cells. Here, we demonstrate that both arms come together to form a program for lung...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Aug 29:S0092-8674(24)00905-X. doi: 10.1016/j.cell.2024.08.014. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Epithelial-to-mesenchymal transitions (EMTs) and extracellular matrix (ECM) remodeling are distinct yet important processes during carcinoma invasion and metastasis. Transforming growth factor β (TGF-β) and RAS, signaling through SMAD and RAS-responsive element-binding protein 1 (RREB1), jointly trigger expression of EMT and fibrogenic factors as two discrete arms of a common transcriptional response in carcinoma cells. Here, we demonstrate that both arms come together to form a program for lung adenocarcinoma metastasis and identify chromatin determinants tying the expression of the constituent genes to TGF-β and RAS inputs. RREB1 localizes to H4K16acK20ac marks in histone H2A.Z-loaded nucleosomes at enhancers in the fibrogenic genes interleukin-11 (IL11), platelet-derived growth factor-B (PDGFB), and hyaluronan synthase 2 (HAS2), as well as the EMT transcription factor SNAI1, priming these enhancers for activation by a SMAD4-INO80 nucleosome remodeling complex in response to TGF-β. These regulatory properties segregate the fibrogenic EMT program from RAS-independent TGF-β gene responses and illuminate the operation and vulnerabilities of a bifunctional program that promotes metastatic outgrowth.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39243762/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240910223724&v=2.18.0.post9+e462414">39243762</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.08.014>10.1016/j.cell.2024.08.014</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39243762</guid>
<pubDate>Sat, 07 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Jun Ho Lee</dc:creator>
<dc:creator>Francisco J Sánchez-Rivera</dc:creator>
<dc:creator>Lan He</dc:creator>
<dc:creator>Harihar Basnet</dc:creator>
<dc:creator>Fei Xavier Chen</dc:creator>
<dc:creator>Elena Spina</dc:creator>
<dc:creator>Liangji Li</dc:creator>
<dc:creator>Carles Torner</dc:creator>
<dc:creator>Jason E Chan</dc:creator>
<dc:creator>Dig Vijay Kumar Yarlagadda</dc:creator>
<dc:creator>Jin Suk Park</dc:creator>
<dc:creator>Carleigh Sussman</dc:creator>
<dc:creator>Charles M Rudin</dc:creator>
<dc:creator>Scott W Lowe</dc:creator>
<dc:creator>Tuomas Tammela</dc:creator>
<dc:creator>Maria J Macias</dc:creator>
<dc:creator>Richard P Koche</dc:creator>
<dc:creator>Joan Massagué</dc:creator>
<dc:date>2024-09-07</dc:date>
<dc:source>Cell</dc:source>
<dc:title>TGF-β and RAS jointly unmask primed enhancers to drive metastasis</dc:title>
<dc:identifier>pmid:39243762</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.08.014</dc:identifier>
</item>
<item>
<title>A focus on two rapidly expanding fields: cardio-oncology and genetics</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39242083/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240910223724&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 7;45(34):3095-3099. doi: 10.1093/eurheartj/ehae556.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39242083/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240910223724&v=2.18.0.post9+e462414">39242083</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae556>10.1093/eurheartj/ehae556</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39242083</guid>
<pubDate>Fri, 06 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2024-09-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>A focus on two rapidly expanding fields: cardio-oncology and genetics</dc:title>
<dc:identifier>pmid:39242083</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae556</dc:identifier>
</item>





























</channel>
</rss>